These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37582248)

  • 1. Efficacy of Biosimilar Infliximab-Dyyb in Non-Infectious Uveitis.
    Zaguia F; Randerson EL; Moorthy RS; Goldstein DA
    Ocul Immunol Inflamm; 2024 Oct; 32(8):1517-1521. PubMed ID: 37582248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrence Rates of Inflammation after Switching from the Originator Infliximab to Biosimilar Infliximab-abda for Noninfectious Uveitis.
    Deaner JD; Srivastava SK; Hajj-Ali RA; Lowder CY; Venkat AG; Baynes K; Sharma S
    Am J Ophthalmol; 2021 May; 225():172-177. PubMed ID: 32795432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Systematic Switch From Originator Infliximab to Biosimilar Infliximab in Patients With Non-Infectious Uveitis.
    Kumar N; Follestad T; Sen HN; Austeng D
    Am J Ophthalmol; 2021 May; 225():178-184. PubMed ID: 33121931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb.
    Bhat S; Altajar S; Shankar D; Zahorian T; Robert R; Qazi T; Shah B; Farraye FA
    J Manag Care Spec Pharm; 2020 Apr; 26(4):410-416. PubMed ID: 32223602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study.
    Ho SL; Niu F; Pola S; Velayos FS; Ning X; Hui RL
    BioDrugs; 2020 Jun; 34(3):395-404. PubMed ID: 32103457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting.
    Baker JF; Bakewell C; Dikranian A; Lam G; O'Brien J; Moore PC; Yu M; Hur P; Masri KR
    Rheumatol Ther; 2024 Jun; 11(3):841-853. PubMed ID: 38507187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world experience with biosimilar infliximab-adba and infliximab-dyyb among infliximab-naïve patients with inflammatory bowel disease in the Veterans Health Administration.
    Patel S; Walsh J; Pinnell D; Pei S; Chen W; Rojas J; Rathod A; Johnson J; Gawron A; Curtis JR; Baker JF; Cannon GW; Wu D; Lai M; Sauer BC
    Medicine (Baltimore); 2024 Sep; 103(37):e39476. PubMed ID: 39287304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study.
    Haifer C; Srinivasan A; An YK; Picardo S; van Langenberg D; Menon S; Begun J; Ghaly S; Thin L
    Med J Aust; 2021 Feb; 214(3):128-133. PubMed ID: 33070332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P013 Resolution of Infliximab Associated Infusion Hypersensitivity After Switching to Biosimilar Infliximab-dyyb.
    Irani M; Bryant R; Lofton H; Abraham B
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S3. PubMed ID: 37461933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study).
    Abraham B; Eksteen B; Nedd K; Kale H; Patel D; Stephens J; Shelbaya A; Chambers R; Soonasra A
    Adv Ther; 2022 May; 39(5):2109-2127. PubMed ID: 35296993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment.
    Riller Q; Cotteret C; Junot H; Benameur N; Haroche J; Mathian A; Hie M; Miyara M; Tilleul P; Amoura Z; Cohen Aubart F
    J Neurol; 2019 May; 266(5):1073-1078. PubMed ID: 30739183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
    Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F
    J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes and cost savings of a nonmedical switch to a biosimilar in children/young adults with inflammatory bowel disease.
    McNicol M; Abdel-Rasoul M; McClinchie MG; Morris GA; Boyle B; Dotson JL; Michel HK; Maltz RM
    J Pediatr Gastroenterol Nutr; 2024 Mar; 78(3):644-652. PubMed ID: 38334232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): Study protocol for an interventional, multicenter, open-label, single-arm and noninferiority clinical trial with clinical, ultrasound, and biomarker assessments.
    Kawashiri SY; Shimizu T; Sato S; Morimoto S; Kawazoe Y; Sumiyoshi R; Hosogaya N; Fukushima C; Yamamoto H; Kawakami A
    Medicine (Baltimore); 2020 Jul; 99(30):e21151. PubMed ID: 32791688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of Rapid Infliximab Biosimilar Infusions in Patients With Inflammatory Bowel Disease.
    Kim JY; Bhat S
    Ann Pharmacother; 2022 Mar; 56(3):280-284. PubMed ID: 34192881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of non-medical infliximab biosimilar switching in ocular inflammatory diseases: A case series from a tertiary care center.
    Dolinko AH; Morvey DE; Apoorva S; Chikovsky M; Anesi SD; Foster CS
    Eur J Ophthalmol; 2024 May; 34(3):774-780. PubMed ID: 37671431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
    Høivik ML; Buer LCT; Cvancarova M; Warren DJ; Bolstad N; Moum BA; Medhus AW
    Scand J Gastroenterol; 2018 Jun; 53(6):692-699. PubMed ID: 29852793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab use in the Netherlands: Uptake and characteristics of originator and biosimilars over time.
    Overbeek JA; Kuiper JG; Bakker M; van den Bemt BJFB; Herings RMC
    Br J Clin Pharmacol; 2022 Feb; 88(4):1804-1810. PubMed ID: 34571570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease.
    Huoponen S; Eberl A; Räsänen P; Roine RP; Sipponen T; Arkkila P; Blom M
    Medicine (Baltimore); 2020 Jan; 99(2):e18723. PubMed ID: 31914087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
    Ther Drug Monit; 2019 Jun; 41(3):317-324. PubMed ID: 30633088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.